Unless there are contraindications to the use of aspirin, aspirin should be used to treat
patients with acute myocardial infarction (MI) and continued indefinitely to decrease vascular …

Background: New antiplatelet drugs are being developed and many clinical trials evaluating
the benefits of antiplatelet drugs for the secondary prevention of ischemic events in patients …

Aspirin should be used to treat patients with acute myocardial infarction (MI) and continued
indefinitely to reduce vascular death, nonfatal MI, and nonfatal stroke. Clopidogrel added to …

Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …

PURPOSE: Clopidogrel is more effective than aspirin in preventing recurrent vascular
events, but concerns about its cost-effectiveness have limited its use. We evaluated the cost …

Aggressive secondary prevention is critical to improving long‐term outcomes in patients with
ischemic coronary artery disease, cerebrovascular disease, and peripheral artery disease …

Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and
other serious vascular events in patients with a history of previous vascular events or known …

Unless there are contraindications to the use of aspirin, aspirin should be used in treating
patients with acute myocardial infarction (MI) and continued indefinitely to reduce vascular …

Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic
stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or …

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …